Further evidence for favorable cost-effectiveness of elderly influenza vaccination

  title={Further evidence for favorable cost-effectiveness of elderly influenza vaccination},
  author={Maarten Jacobus Postma and Rob Baltussen and Abraham M. Palache and Jan C. Wilschut},
  journal={Expert Review of Pharmacoeconomics \& Outcomes Research},
  pages={215 - 227}
Vaccination represents the single most cost-effective strategy to avert influenza-related morbidity, mortality and economic consequences. This review presents an analysis of the pharmacoeconomic aspects of influenza vaccination of the elderly. The methodology of the analysis focuses on the main drivers of the pharmacoeconomic profile of elderly influenza vaccination, in particular the vaccine effectiveness in terms of prevention of hospitalization and mortality, the background incidence of… 

Influenza vaccines in low and middle income countries

Most findings are in line with evidence from high-income countries highlighting that influenza vaccine is likely to provide value for money, but serious methodological limitations do not allow drawing conclusions on cost-effectiveness of influenza vaccination in middle income countries.

The sustainability of influenza vaccination programs: considerations and perspectives from Italy

A review sums up the key elements of influenza vaccine sustainability and makes suggestions for improving the organizational structure of the present initiatives.

Medical and economic burden of influenza in the elderly population in central and eastern European countries

This study most probably underestimates the real burden of influenza, however the public health problem is recognized worldwide, and will further increase with population aging, and to fully quantify theurden of influenza in CEE, influenza reporting systems should be standardized.

A systematic review of economic evaluations of seasonal influenza vaccination for the elderly population in the European Union

Most studies suggest that vaccination is cost-effective (seven of eight studies identified at least one cost- effective scenario), and Integrated, controlled prospective clinical and economic evaluations and surveillance data are needed to improve the evidence base.

Cost Effectiveness of Oseltamivir Treatment for Patients with Influenza-Like Illness Who Are at Increased Risk for Serious Complications of Influenza

It is suggested that at-risk people presenting with ILI to a GP could be offered oseltamivir at favourable cost effectiveness or even cost savings in the Dutch setting compared with symptom relief with analgesics only.

Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies

Given the importance of knowing the impact of changes to influenza policy, such complexities need careful treatment using tools such as population-based trial designs, meta-analyses, time-series analyses and transmission dynamic models.

Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges

It is argued that it is important to more fully consider some important issues and challenges of vaccination programmes targeted at older adults and the elderly in high-income countries.

Model Comparisons of the Effectiveness and Cost-Effectiveness of Vaccination: A Systematic Review of the Literature.

The Impacts of Implementing Primary Care Indicators and Related Financial Incentives on the Trends of Vaccination Coverage Against Influenza Among Elderly People in Hungary

The implementation of indicators system and related financial incentives could not exploit the potential opportunities in the aspect of increasing the flu vaccination coverage among elderlies in Hungary and should be achieved with other options such as raising the awareness among people and implementing an effective, follow up system.

Predictors of influenza vaccination among elderly: a cross-sectional survey in Greece

Only a small proportion of those over the age of 60 had received the influenza vaccine, which indicates the impact that a future outbreak of seasonal influenza could exert upon vulnerable groups.



Pharmacoeconomics of Influenza Vaccination in the Elderly

Relatively favourable cost-effectiveness among non-high-risk elderly justifies universal influenza vaccination of the elderly from a pharmacoeconomic point of view.

Economic Evaluations of Influenza Vaccination in the Elderly

The cost-benefit and cost-effectiveness results in elderly individuals support the recommendations for vaccination of all persons of 65 years and over that are currently endorsed in the US, Australia, New Zealand and many European countries.

Cost-effective analysis of influenza vaccination in the elderly

Analysis of the cost-effectiveness of vaccinating all elderly persons against influenza A on an annual basis found significant potential savings resulting from the implementation of an influenza control program in both the community and nursing home setting.

Economic evaluation of influenza vaccination. Assessment for The Netherlands.

Influenza vaccination has a cost-effectiveness ratio that is better than or comparable to that of other implemented Dutch programmes in the prevention of infectious diseases.

Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: costeffectiveness analyses and implications for The Netherlands

It is concluded that cost-effectiveness of vaccination against invasive pneumococcal infections for Dutch elderly is favorable and justifies implementation from a pharmacoeconomic point of view.

Influenza Vaccination: Cost-effectiveness and Public Policy

The analysis indicates the need for epidemiologic research on the extent of influenza and the mechanism of its spread and raises the issue of public policy to promote influenza vaccination among high-risk persons as a low-cost, preventive technology.

Influenza vaccination in community-dwelling elderly: impact on mortality and influenza-associated morbidity.

The results indicate that, in a season of mild influenza activity and good antigenic match between vaccine strains and circulating strains, influenza vaccination reduced mortality in the vaccinated population.